Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells

Abstract
Claudin-low breast cancer represents an aggressive molecular subtype that is comprised of mostly triple-negative mammary tumor cells that possess stem cell-like and mesenchymal features. Little is known about the cellular origin and oncogenic drivers that promote claudin-low breast cancer. In this study, we show that persistent oncogenic RAS signaling causes highly metastatic triple-negative mammary tumors in mice. More importantly, the activation of endogenous mutant KRAS and expression of exogenous KRAS specifically in luminal epithelial cells in a continuous and differentiation stage-independent manner induces preneoplastic lesions that evolve into basal-like and claudin-low mammary cancers. Further investigations demonstrate that the continuous signaling of oncogenic RAS, as well as regulators of EMT, play a crucial role in the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics of claudin-low mammary cancer cells.
Funding Information
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA009476, CA228326, CA14876, CA58223, CA117930, CA202917, CA022453)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute
  • Breast Cancer Research Foundation
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute
  • METAvivor